The mission of the Human Biology & Data Sciences (HB&DS) Engine is to discover and validate novel therapeutic targets and biomarkers by leveraging knowledge of the causes of disease from human biology data. This engine consists of cross-trained data scientists, who have backgrounds in biology, chemistry, statistical genetics, and clinical research. HB&DS is driven to create new therapies to address unmet needs in neurology and oncology, as well as to contribute across the pipeline from discovery to clinical research through our close interactions with the other engines within AiM.
To enable end-to-end drug discovery from genetic targets to innovative compounds, the Integrated Biology Engine consists of multi-disciplinary biologists whose expertise spans a wide-range of in vitro and in vivo pharmacology sciences, including gene expression profiling, electrophysiology, flow cytometry, immunohistochemistry, immunology, behavioral analysis, human iPSC-derived cell models, and animal models of tumor and neurodegenerative diseases. By integrating this expertise, we are able to validate therapeutic concepts by taking a functional genomics approach to evaluate genetic variants in human cell systems and in vivo disease models to understand how genetic variation changes the function of targets to cause disease. We seek to generate extensive preclinical data packages for IND filings, which includes preclinical proof-of-concept and translational biomarkers for clinical dose-setting and patient stratification.
The Target Modulation Engine rests at the interface between chemistry and biology. It connects novel therapeutic targets with bioactive compounds through five key capabilities: computational chemistry, structure biology, assay development, compound management, and screening systems, including high throughput screening (HTS). Through collaboration with all engines within AiM, we aim to accelerate drug discovery by developing hypotheses about relevant target modulation mechanisms; experiment-supported structural biology; creation of target specific assays; selection of flexible, strategic screening approaches; and maintaining and providing a Eisai-unique compound collection.
The Integrated Chemistry Engine combines expertise in medicinal, synthetic, screening, structural, translational, and platform chemistry, enabling innovative solutions to be devised for human biology validated targets. Building upon Eisai’s rich history of discovering and commercializing structurally complex fully synthetic natural product-based drugs, we are poised to explore previously inaccessible areas of stereochemically and architecturally complex molecular space to address previously undruggable targets.
The Translational Imaging Engine (TIE) was established to provide in-house, decision‐enabling, preclinical and clinical imaging solutions and strategies using cutting-edge approaches for global drug discovery and translational research. TIE serves as the singular resource for in-vivo imaging expertise and applications across all global Eisai sites and subsidiaries. In house capabilities include the use of non-invasive imaging modalities MRI, CT, SPECT and PET, and radiochemistry for neuroscience, oncology, immunodementia and drug safety. TIE also has in-vitro/ex-vivo capabilities used across the same therapeutic areas, enabling a de-risking approach to validate and characterize drug and imaging biomarker probes. Moreover, TIE has additional capabilities and experience to collaborate on translational imaging strategies for early phase clinical work, including early development of novel PET ligands. Combined, these capabilities provide a data-driven, decision enabling mechanism to support drug discovery and development programs.